Epiomic Epidemiology Series: Cystic Fibrosis Forecast in 9 Major Markets 2015-2025

August 2015 | 36 pages | ID: E8E8C3AAB92EN
Black Swan Analysis limited

Abstracts

Cystic Fibrosis (CF) is an autosomal-recessive disease which affects the secretory glands throughout the body. The disease primarily involves the lung, but can also affect other organs. This report provides the current prevalent population for CF across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of CF. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of CF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for CF include:

• Respiratory complications
• Gastrointestinal complications
• Osteoporosis
• Cirrhosis
• Cystic Fibrosis Related Diabetes
• Infertility

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global CF’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of CF and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on CF’s prevalent population.
• Identify sub-populations within CF which require treatment.
• Gain an understanding of the specific markets that have the largest number of CF patients.

Contents

Introduction
Cause of the Disease
Risk Factors and Prevention
Diagnosis of the Disease
Variation by Geography/ Ethnicity
Disease Prognosis and Clinical Course
Key Co-Morbid Conditions / Features associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Prevalence for Cystic Fibrosis
  Forced expiratory Volume (FEV)
  Cystic Fibrosis with Mutation Type
  Respiratory Complications of Cystic Fibrosis
  Other Co-morbidities Regarding Cystic Fibrosis
Abbreviations used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES & FIGURES

Prevalence of CF, total (000s)
Prevalence of CF, males (000s)
Prevalence of CF, females (000s)
Forced Expiratory Volumes of CF Patients, total (000s)
Cystic Fibrosis Patients with Mutation type, total (000s)
Prevalence of Asthma in Patients with CF, total (000s)
Prevalence of Pneumonia in Patients with CF, total (000s)
Prevalence of CF Related Diabetes in Patients with CF, total (000s)
Prevalence of Pancreatic Insufficiency in Patients with CF ,total (000s)
USA Prevalence of CF by 5-yr age cohort, males (000s)
USA Prevalence of CF by 5-yr age cohort, females (000s)
France Prevalence of CF by 5-yr age cohort, males (000s)
France Prevalence of CF by 5-yr age cohort, females (000s)
Germany Prevalence of CF by 5-yr age cohort, males (000s)
Germany Prevalence of CF by 5-yr age cohort, females (000s)
Italy Prevalence of CF by 5-yr age cohort, males (000s)
Italy Prevalence of CF by 5-yr age cohort, females (000s)
Spain Prevalence of CF by 5-yr age cohort, males (000s)
Spain Prevalence of CF by 5-yr age cohort, females (000s)
United Kingdom Prevalence of CF by 5-yr age cohort, males (000s)
United Kingdom Prevalence of CF by 5-yr age cohort, females (000s)
Brazil Prevalence of CF by 5-yr age cohort, males (000s)
Brazil Prevalence of CF by 5-yr age cohort, females (000s)
Japan Prevalence of CF by 5-yr age cohort, males (000s)
Japan Prevalence of CF by 5-yr age cohort, females (000s)
India Prevalence of CF by 5-yr age cohort, males (000s)
India Prevalence of CF by 5-yr age cohort, females (000s)